- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03669939
Toward Safer Opioid Prescribing for Chronic Pain in High Risk Populations (TOWER)
October 8, 2020 updated by: Jessica Robinson-Papp, Icahn School of Medicine at Mount Sinai
Toward Safer Opioid Prescribing for Chronic Pain in High Risk Populations: Implementing the Centers for Disease Control Guideline (CDC) Guideline in the Primary Care HIV Clinic.
The overarching plan for TOWER is to develop and test an algorithmic version of the Center for Disease Control Guidelines (CDCG) tailored for a specific primary care setting, the HIV primary care clinic.
This CDCG intervention incorporates communication and implementation strategies tailored for the HIV primary care setting, and enabled with technology (an app for use by patients and EMR tools for providers).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
However, according to a 2014 AHRQ report, there have been no studies evaluating the effectiveness of any prescription opioid risk mitigation strategies.
Furthermore, due to ambiguity in some of the CDCG recommendations and the challenging nature of the patient-provider opioid conversation, the success of the CDCG may hinge on the manner in which it is implemented in individual care settings.
Thus it is unclear what the true effect of the CDCG will be.
The investigators believe that for the CDCG to have the greatest likelihood of achieving its goals of improving prescription opioid safety without causing unintended effects (e.g.
exacerbation of pain, disruption of other aspects of care), its recommendations will need to be skillfully communicated.
Furthermore, because of this "human element"and other sources of variability, documenting the effectiveness of the CDCG will require standardization of implementation.
The overarching plan for TOWER is to develop and test an algorithmic version of the CDCG tailored for a specific primary care setting, the HIV primary care clinic.
This CDCG intervention incorporates communication and implementation strategies tailored for the HIV primary care setting, and enabled with technology (an app for use by patients and EMR tools for providers).
Achieving this goal has involved soliciting input from the HIV community using the method of Public Deliberation (PD) in the setting of two Citizen' s Panels, each with ~22 HIV-infected participants and lasting one day; and using the information obtained from the deliberative process to inform the development of the CDCG intervention.
The investigators now plan to test the CDCG intervention for feasibility.
Study Type
Observational
Enrollment (Actual)
42
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 11101
- Icahn School of Medicine at Mount Sinai
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Primary Care Providers who treat HIV patients in the Institute of Advanced Medicine Institute at Mount Sinai Health System
Description
Inclusion Criteria:
- Attending physician or advance practice provider in one of the Institute of Advanced Medicine (IAM) clinics
- Designated PCP for at least 5 patients to whom he/she prescribes opioids
- Willing and able to adhere to study procedures including randomization, and refraining from discussion of study procedures with other clinical staff or patients
Exclusion Criteria:
- Unwillingness to undergo randomization
- Plans to leave IAM within the study period.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Communication strategy
Primary Care providers who see HIV patients and follow them on opiates for chronic pain to receive communication strategies developed by the study team wit the guidance from the HV community and providers
|
Communication Strategy The intervention consists of a handbook that refers to the CDC Guidelines with tools and communication strategies that the PCP can use when assessing their patients who are on opioids.
The Handbook will have a description of the Ohm-app and the information the PCP can retrieve from the dashboard in their medical record.
They will also be provided a template to use when seeing the patient to use as guide and as documentation.
|
Standard of Care
Primary Care Providers - who see HIV patients and follow them on opiates for chronic pain will receive education on the the standard information about the CDC Guidelines
|
The standard information about the CDC Guidelines and no other information that is available through the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of eligible PCPs who successfully complete randomization
Time Frame: 18 months
|
Feasibility of recruitment and randomization of PCPs, reflected by the proportion of eligible PCPs who successfully complete randomization (where the denominator is the total number of PCPs offered participation).
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of items in the CDCG intervention which were adhered to
Time Frame: 18 months
|
Maintenance of intervention fidelity will be ascertained using the audiotaped data from the clinic visits, and will be described as the percentage of items in the CDCG intervention which were adhered to.
|
18 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Standard of Care
Time Frame: 18 months
|
Per the CDC guideline (CDCG) for prescribing opioids in general primary care settings, there are 12 recommendations providers must follow in order to reduce prescription opioid-related harms while maintaining pain control and function.
In order to monitor providers' adherence to the guideline and to establish appropriateness of "usual care", within the control arm, we will implement the CDCG Adherence Assessment Tool.
The CDCG Adherence tool will score patients' EMR notes and will consist of 10-items relevant to the 12 recommendations outlined in the CDCG.
If the CDCG recommendations have been denoted in the EMR note, each item will receive points based on a 1-2 numeric scale (max of 16 points).
All clinical visits completed during the duration of the study will be scored.
A higher number indicating a favorable outcome of adherence to the CDCG guideline.
|
18 months
|
Primary Outcome Measure determination
Time Frame: 18 months
|
The best choice of a primary outcome measure for future studies.
|
18 months
|
CDCG Adherence Assessment Tool
Time Frame: 18 months
|
Two tools will be provided to Intervention providers, an Opioid Managing-app (OM-app) and an EMR note template.
The acceptability of the OM-app and EMR tool within the clinical setting will be measured.
The OM-app was designed to help collect data needed by the PCP to follow the CDC guideline.
The OM-app will contact patients once daily with a link which will take them to a series of questions relevant to their pain management.
The app will be responsible for aggregating this data into a report form that the PCP can utilize to facilitate a discussion with the patient and to populate an EMR progress note.
The EMR note template will be provided to intervention providers in order to import data collected from the app into a patient's EMR during clinic visits.
As with the control arm, the CDCG Adherence Assessment Tool will be implemented which will score patients' EMR notes on a 1-2 numeric scale (max of 16 points).
A higher number indicating a favorable outcome.
|
18 months
|
Current Opioid Misuse Measure (COMM)
Time Frame: 18 months
|
17-item, each scored 0 (never) to 4 (very often) with total scale from 0 - 68, higher score indicating more opioid misuse
|
18 months
|
Self-Reported Misuse, Abuse, and Diversion (SR-MAD)
Time Frame: 18 months
|
Self-Reported Misuse, Abuse and Diversion of Prescription Opioids (SR-MAD) instrument consists of 18 self-report items 0-10 numerical rating scale.
Total scale from 0 to 180, with higher score indicating worse outcomes.
|
18 months
|
Brief Pain Inventory (BPI)
Time Frame: 18 months
|
Brief Pain Inventory (BPI) is a 9-item instrument with total score from 0 to 10, with higher score indicating worse outcomes.
|
18 months
|
Hospital Anxiety and Depression Scale (HADS)
Time Frame: 18 months
|
14-items scale with responses scored from 0-3, scores for each subscale from 0 (normal) to 21 (severe symptoms).
Scores for the entire scale is 0 to 42, with higher score indicating more distress.
|
18 months
|
Trust in Provider Scale (TIPS)
Time Frame: 18 months
|
11-items scale scored on a 5-point likert scale from 1 (strongly disagree) to 5 (strongly agree).
A 52 Freburger et al summary measure of trust is obtained by taking the unweighted mean of the responses to the 11 questions and transforming that value to a 0-100 scale.
Higher scores reflect greater trust.
|
18 months
|
HIV Stigma Scale (HSS)
Time Frame: 18 months
|
40-items using a 4 point likert scale 1 (strongly disagree) to 4 (strongly agree), with full scale from 40 to 160.
Higher score indicates poorer outcomes
|
18 months
|
Brief Perceived Ethnic Discrimination Questionnaire-Community Version (BPEDQ-CV)
Time Frame: 18 months
|
17-item scale on a summed average likert-type scale from 1 (never happened) to 5 (happened very often).
Higher score indicated perception of discrimination.
|
18 months
|
Internalized Stigma of Chronic Pain (ISCP)
Time Frame: 18 months
|
Sum average score on 4-point Likert-type scale (1 = strongly disagree, 2 = disagree, 3 = agree, 4 = strongly agree).
Higher score indicates more stigma of chronic pain.
|
18 months
|
Consumer Assessment of Healthcare Providers and System (CAHPS®) Clinician & Group Survey (CG-CAHPS)
Time Frame: 18 months
|
Composite score converted to numerical scale from 0 (never) to 100 (always).
and one overall rating of the doctor on a scale from 0 to 10, with higher score showing a more favorable outcome.
|
18 months
|
Opioid Therapy PROVIDER Survey
Time Frame: 18 months
|
10 question survey, sum average score on a 5-point likert scale 1 (strongly agree) to 5 (strongly disagree)
|
18 months
|
Intervention provider post- survey
Time Frame: 18 months
|
6 question survey, intended for provider participants who have been randomized into the intervention arm.
The survey includes a 5-point Likert-scale (5=strongly agree, 4=agree, 3=neutral, 2=disagree, 1=strongly disagree) with a high sum average indicating a satisfactory outcome.
|
18 months
|
Modified ACTG Adherence
Time Frame: 18 months
|
A self-reported questionnaire comprised of 8 items.
Only item #4 will be used as a percentage of their HIV medication intake, on a scale from 0-100%. .
A higher percentage indicating a favorable outcome..
|
18 months
|
Quantitative Analgesic Questionnaire (QAQ)
Time Frame: 18 months
|
Tool for quantifying how much pain meds a patient is taking, by calculating the total weekly doses, the QAQ ("as reported"), and comparing them to the regimen score previously established by physicians who actively treat chronic pain.
Regimens are rated on scale from 1 (small amount of meds) to 5 (large amt of meds). 1 QAQ point is assign for taking any opioids at all, & an additional point assign for every equivalent of 100 mg of oral morphine used per week (1-99 mg = 1 pt; 100-199 = 2 pts, etc.).
For all other oral meds, 1 point for taking the meds at all, & an additional point for each 25% of the maximum dose taken (1-24% = 1 pt; 25-49% = 2 points, etc.).
For topicals, 1 point for each topical reports using regardless of dose or frequency.
No upper limit to the amt of QAQ points a patient may accrue.
The lowest number of QAQ is 0=no medication.
A higher discrepancy between the sum average of QAQ points and "as prescribed" points will indicate a lower adherence rate.
|
18 months
|
TOWER Post Clinic Visit Interview
Time Frame: 18 months
|
This is an 18 item questionnaire of the patients experience after a clinical session with their provider.
There are 2 scores, one score will be a sum average on a scale from 0-6 for questions 1-6.
The second score will be a sum average on a scale from 0-50 for questions 8-12.
A higher scored indicating a favorable outcome.
|
18 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 5, 2018
Primary Completion (Actual)
September 30, 2020
Study Completion (Actual)
September 30, 2020
Study Registration Dates
First Submitted
August 22, 2018
First Submitted That Met QC Criteria
September 11, 2018
First Posted (Actual)
September 13, 2018
Study Record Updates
Last Update Posted (Actual)
October 9, 2020
Last Update Submitted That Met QC Criteria
October 8, 2020
Last Verified
October 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GCO 17-0154
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Clinical information that is relevant to the provider or patient
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Pain
-
Pain ConcernThe Thistle Foundation; Health and Social Care Alliance Scotland (the ALLIANCE) and other collaboratorsCompletedChronic Pain | Chronic Pain Syndrome | Chronic Pain, Widespread | Chronic Pain Due to Trauma | Chronic Pain Due to Malignancy (Finding) | Chronic Pain Due to Injury | Chronic Pain Post-Procedural | Chronic Pain HipUnited Kingdom
-
Consorci Sanitari de l'Alt Penedès i GarrafRecruitingChronic Post Operative Pain | Chronic Post-surgical Pain | Chronic Knee PainSpain
-
University of Alabama, TuscaloosaPatient-Centered Outcomes Research Institute; East Carolina University; Whatley...CompletedPain | Chronic Pain | Chronic Pain Syndrome | Widespread Chronic Pain | Chronic Pain Due to InjuryUnited States
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Evolve Restorative CenterFlowonix Medical; Celéri Health, Inc.; Advanced Infusion SolutionsCompletedPain, Chronic | Pain, Intractable | Chronic Nonmalignant PainUnited States
-
University of UtahRecruitingChronic Pain | Chronic Pain Syndrome | Widespread Chronic PainUnited States
-
Assiut UniversityNot yet recruiting
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
-
Istanbul UniversityCompletedLow Back Pain, Mechanical, Biofeedback, Pain, Chronic
-
Apurano Pharmaceuticals GmbHRecruitingPain | Lower Back Pain | Back Pain | Chronic Pain | Pain, Chronic | Chronic Pain Syndrome | Pain Syndrome | Lower Back Pain ChronicGermany
Clinical Trials on Communication Strategy
-
Icahn School of Medicine at Mount SinaiMoi UniversityCompletedHypertension | High Blood PressureKenya
-
Maebashi Red Cross HospitalCompletedPalliative CareJapan
-
State University of New York at BuffaloCompletedCommunication ResearchUnited States
-
Pontificia Universidad Catolica de ChileUniversity of Chile; Universidad de La FronteraCompletedCritical Illness | Covid19 | Mechanical VentilationChile
-
Brigham and Women's HospitalNational Institutes of Health (NIH)Not yet recruiting
-
Washington University School of MedicineNational Cancer Institute (NCI)Active, not recruitingHuman Papillomavirus VaccinesUnited States
-
Imperial College LondonImperial College Healthcare NHS TrustEnrolling by invitationBehavioural Science Interventions to Improve Health EquityUnited Kingdom
-
Washington University School of MedicineEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingCovid19 | Intellectual Disability | Developmental Disability | Child Development DisorderUnited States
-
Swansea UniversityCompletedControl Condition | Positive Communication (Primary) | Negative CommunicationUnited Kingdom
-
Hugo W. Moser Research Institute at Kennedy Krieger...HRSA/Maternal and Child Health BureauCompleted